Trial Condition(s):

Ophthalmology, Macular Degeneration

Study to Assess the Effectiveness of Existing Anti vascUlar Endothelial Growth Factor (Anti VEGF) in Patients With Wet Age-related Macular Degeneration (wAMD) (AURA) (AURA)

Bayer Identifier:

15913

ClinicalTrials.gov Identifier:

NCT01447043

EudraCT Number:

Not Available

Study Completed

Trial Purpose

Retrospective, non-interventional, observational multi-center field study. Patients diagnosed with wet Age-related macular degeneration (wAMD) and having started treatment with ranibizumab between January 1, 2009 and August 31, 2009 must be consecutively screened and, if eligible, enrolled. Patients will be followed up at maximum until August 31, 2011. Switch to any other Anti vascUlar endothelial growth factor (anti VEGF) treatment will be documented and followed up. For each patient, demographics, medical history, administered treatments, results of ocular and visual assessments and other tests (where available) will be documented.

Inclusion Criteria
-  Diagnosis of wet age-related macular degeneration
 -  Start of Anti vascUlar endothelial growth factor (anti VEGF) therapy with ranibizumab between January 1, 2009 and August 31, 2009
 -  Informed consent form signed, where required
Exclusion Criteria
-  Participation in an investigational study during anti-VEGF therapy (from start up to August 31, 2011) that involved treatment with any drug or medical device

Trial Summary

Enrollment Goal
2609
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
No Drug
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, Germany

Status
Completed
 
Locations

Investigative Site

Many Locations, United Kingdom

Status
Completed
 
Locations

Investigative Site

Many Locations, France

Status
Completed
 
Locations

Investigative Site

Many Locations, Japan

Status
Terminated
 
Locations

Investigative Site

Many Locations, Italy

Status
Completed
 
Locations

Investigative Site

Many Locations, Australia

Status
Terminated
 
Locations

Investigative Site

Many Locations, Venezuela

Status
Completed
 
Locations

Investigative Site

Many Locations, Ireland

Status
Completed
 
Locations

Investigative Site

Many Locations, Canada

Status
Completed
 
Locations

Investigative Site

Many Locations, Netherlands

Status
Completed
 

Trial Design